Endocrine Abstracts

Background: Inclisiran is the first clinically available small interfering RNA (siRNA)-based treatment, has been shown to reduce pro-atherogenic lipoproteins in patients with or without familial hypercholesterolemia (FH), diabetes mellitus (DM), or atherosclerotic cardiovascular disease (ASCVD), but has not been evaluated in Middle Eastern populations.Methods: Retrospective review of patients initiating inclisiran treatment for any indication at our cent...

Background: Cardiovascular disease (CVD) is a leading cause of mortality. Childhood obesity is a major contributor to CVD. Atherogenic index of plasma (AIP) is an indicator of risk of atherosclerotic CVD. Associations between childhood obesity and CVD risk in the region remains under-explored. We aim to investigate this association as a predictor of CVD in this young population.Methods: Patients who attended our Centre (2009-2019), age ≤19 years an...